← All companies
MASIMO CORP
MASI - CIK 0000937556
Market cap$9.43 B
Rank#972
SEC filings1,510
MASIMO CORP trades as MASI and has a market capitalization of $9.43 B, making it the #972 largest US-listed company by market value. In its fiscal 2026 annual report the company posted revenue of $1.53B, up 9.4% from the prior year and net income of -$151.50M. This page tracks MASIMO CORP through 1,510 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$1.53BFY 2026
Net income (latest FY)-$151.50MFY 2026
Operating cash flow (latest FY)$217.80MFY 2026
Total assets (latest FY)$1.70BFY 2025
Gross margin61.9%latest FY
Net margin-9.9%latest FY
Financial performance
Over the last 10 fiscal years MASIMO CORP's revenue grew from $712.90M to $1.53B, a compound annual growth rate of 7.9%. Net profit margin compressed from 43.6% to -9.9% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $9.43 B
- Share price (derived)market cap / shares outstanding
- $179.95
- EPS (diluted)FY 2026
- $-2.80
- Shares outstandingas of 2026-04-04
- 0.05B
- Total equityas of 2026-04-04
- $788.90M
- Return on equity
- -19.2%
- Long-term debtas of 2026-04-04
- $452.00M
- Cash & equivalentsas of 2026-04-04
- $124.60M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Major company event | 8-K | 2026-05-04 |
Recent press releases
- Masimo Shareholders Approve Acquisition by Danaher2026-05-04
Katie Szyman, Chief Executive Officer of Masimo, stated: “We thank our shareholders for their strong support of this important milestone for Masimo. The Merger delivers compelling value and positions Masimo for continued global growth as an independent operating company within Danaher’s Diagnostics segment. We look forward to completing this process and, together with Danaher, continuing our mission of developing innovative technologies that empower clinicians to transform patient care.”
- Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study2026-04-28
_NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns_
- Masimo to be Acquired by Danaher for $180.00 Per Share2026-02-17
Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (“Danaher”) will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the “Transaction”).
- Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 262026-02-12
_Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)_
Similar companies
The largest companies sharing MASIMO CORP's SEC industry classification (electromedical & electrotherapeutic apparatus).
Frequently asked questions
What is MASIMO CORP's market cap?
MASIMO CORP (MASI) has a market capitalization of $9.43 B as of 2026-06-10, ranking #972 among US-listed companies.
How much revenue does MASIMO CORP make?
MASIMO CORP reported revenue of $1.53B for fiscal year 2026, an increase of 9.4% year over year.
Is MASIMO CORP profitable?
In its latest fiscal year MASIMO CORP reported a net loss of $151.50M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.